According to the latest report by IMARC Group, titled “Cell Therapy Market Report by Cell Type (Stem Cell, Non-stem Cell), Therapy Type (Autologous, Allogeneic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), End User (Hospitals and Clinics, Academic and Research Institutes), and Region 2025-2033,” the global cell therapy market size reached USD 15.7 Billion in 2024. Cell therapy, also known as cytotherapy, is a cutting-edge medical treatment that harnesses the power of living cells to treat various diseases and conditions. It relies on the unique abilities of cells to repair, replace, or regenerate damaged or dysfunctional tissues within the body. It is widely used for various medical applications, such as cancer treatment and regenerative medicine. It involves the isolation, manipulation, and transplantation of cells to restore or enhance the natural healing processes of the body. It can be customized to target specific tissues or diseases. It is widely used in cancer treatment to recognize and attack cancer cells while sparing healthy ones and reducing collateral damage. Besides this, as it often results in fewer side effects compared to many conventional treatments, the demand for cell therapy is rising across the globe.
Global Cell Therapy Market Trends:
The increasing prevalence of chronic diseases, such as cancer, cardiovascular disorders, and autoimmune conditions, represents one of the primary factors driving the market. Apart from this, rapid advancements in stem cell research, genetic engineering, and cell culturing techniques are enabling the development of increasingly sophisticated and effective cell-based therapies. Furthermore, regulatory agencies worldwide are undertaking several steps to streamline the approval process for cell therapies, which is strengthening the growth of the market. This regulatory support is accelerating the development and commercialization of cell therapies, reducing the time and costs involved in bringing these treatments to market. Looking forward, the market value is projected to reach USD 60.8 Billion by 2033, expanding at a CAGR of 14.51% during 2025-2033.
Market Summary:
- Based on the cell type, the market has been bifurcated into stem cell (bone marrow, blood, umbilical cord-derived, adipose-derived stem cell, and others) and non-stem cell. Stem cell (bone marrow, blood, umbilical cord-derived, adipose-derived stem cell, and others) currently dominates the market.
- On the basis of the therapy type, autologous represents the largest segment, followed by the allogeneic.
- Based on the therapeutic area, the market has been classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. At present, malignancies hold the biggest market share.
- On the basis of the end user, the market has been divided into hospitals and clinics, academic and research institutes.
- Region-wise, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, North America exhibits a clear dominance in the market.
- The competitive landscape of the market has also been examined, with some of the key players being AlloSource, Anterogen Co. Ltd., Cells for Cells, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals, Kolon TissueGene Inc., MEDIPOST, Mesoblast Limited, NuVasive, Stemedica Cell Technologies Inc., Stempeutics Research Pvt. Ltd, and Vericel Corporation.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2024 |
Historical Period |
2019-2024 |
Forecast Period |
2025-2033 |
Units |
Billion USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
- Cell Type
- Therapy Type
- Therapeutic Area
- End User
- Region
|
Cell Types Covered |
- Stem Cell: Bone Marrow, Blood, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Others
- Non-stem Cell
|
Therapy Types Covered |
Autologous, Allogeneic |
Therapeutic Areas Covered |
Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, Others |
End Users Covered |
Hospitals and Clinics, Academic and Research Institutes |
Regions Covered |
Asia Pacific, Europe, North America, Latin America, the Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
AlloSource, Anterogen Co. Ltd., Cells for Cells, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals, Kolon TissueGene Inc., MEDIPOST, Mesoblast Limited, NuVasive, Stemedica Cell Technologies Inc., Stempeutics Research Pvt. Ltd, Vericel Corporation, etc. |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800